4.6 Article

STAT2 Is Required for TLR-Induced Murine Dendritic Cell Activation and Cross-Presentation

Journal

JOURNAL OF IMMUNOLOGY
Volume 197, Issue 1, Pages 326-336

Publisher

AMER ASSOC IMMUNOLOGISTS
DOI: 10.4049/jimmunol.1500152

Keywords

-

Categories

Funding

  1. National Institute of Allergy and Infectious Diseases Grant [RO1-AI076423]
  2. Pennsylvania Department of Health
  3. National Institutes of Health

Ask authors/readers for more resources

TLR-stimulated cross-presentation by conventional dendritic cells (cDCs) is important in host defense and antitumor immunity. We recently reported that cDCs lacking the type I IFN signaling molecule STAT2 are impaired in cross-presenting tumor Ags to CD8(+) T cells. To investigate how STAT2 affects cross-presentation, we determined its requirements for dendritic cell activation. In this study, we report that STAT2 is essential for the activation of murine female cDCs upon TLR3, -4, -7, and -9 stimulation. In response to various TLR ligands, Stat2(-/-) cDCs displayed reduced expression of costimulatory molecules and type I IFN-stimulated genes. The cDC responses to exogenous IFN-alpha that we evaluated required STAT2 activation, indicating that the canonical STAT1 STAT2 heterodimers are the primary signaling transducers of type I IFNs in cDCs. Interestingly, LPS-induced production of IL-12 was STAT2 and type I IFN receptor (IFNAR) dependent, whereas LPS-induced production of TNF-alpha and IL-6 was STAT2 and IFNAR independent, suggesting a specific role of the IFNAR-STAT2 axis in the stimulation of proinflammatory cytokines by LPS in cDCs. In contrast, R848- and CpG-induced cytokine production was less influenced by the IFNAR-STAT2 axis. Short kinetics and IFNAR blockade studies showed that STAT2 main function is to transduce signals triggered by autocrine type I IFNs. Importantly, Stat2(-/-) cDCs were deficient in cross-presenting to CD8(+) T cells in vitro upon IFN-alpha, CpG, and LPS stimulation, and also in cross-priming and licensing cytotoxic T cell killers in vivo. We conclude that STAT2 plays a critical role in TLR-induced dendritic cell activation and cross-presentation, and thus is vital in host defense.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Article Oncology

Nonsurgical Approaches to Treat Biliary Tract and Liver Tumors

Benjamin L. Green, Michael G. House

SURGICAL ONCOLOGY CLINICS OF NORTH AMERICA (2019)

Article Rheumatology

Persistent Bacteriuria and Antibodies Recognizing Curli/eDNA Complexes FromEscherichia coliAre Linked to Flares in Systemic Lupus Erythematosus

Ryan J. Pachucki, Chelsea Corradetti, Lynne Kohler, Jay Ghadiali, Paul M. Gallo, Lauren Nicastro, Sarah A. Tursi, Stefania Gallucci, Cagla Tukel, Roberto Caricchio

ARTHRITIS & RHEUMATOLOGY (2020)

Article Rheumatology

Preliminary predictive criteria for COVID-19 cytokine storm

Roberto Caricchio, Marcello Gallucci, Chandra Dass, Xinyan Zhang, Stefania Gallucci, David Fleece, Michael Bromberg, Gerard J. Criner

Summary: Researchers developed predictive criteria for COVID-19-associated cytokine storm (CS) and proposed new early predictive criteria to identify CS occurring in patients with COVID-19, which can determine the need for early therapeutic regimen and potentially reduce mortality.

ANNALS OF THE RHEUMATIC DISEASES (2021)

Review Biochemistry & Molecular Biology

Abnormalities of the type I interferon signaling pathway in lupus autoimmunity

Stefania Gallucci, Sowmya Meka, Ana M. Gamero

Summary: Type I interferons (IFNs) play a crucial role in the pathogenesis of Systemic Lupus Erythematosus (SLE), and aberrant IFN signaling can exacerbate SLE. Genetic and epigenetic abnormalities are present in SLE patients. Neutralizing anti-type I IFN receptor antibodies may be a therapeutic strategy.

CYTOKINE (2021)

Article Medicine, Research & Experimental

Context-dependent induction of autoimmunity by TNF signaling deficiency

Tam D. Quach, Weiqing Huang, Ranjit Sahu, Catherine M. M. Diadhiou, Chirag Raparia, Roshawn Johnson, Tung Ming Leung, Susan Malkiel, Peta Gay Ricketts, Stefania Gallucci, Cagla Tukel, Chaim O. Jacob, Martin L. Lesser, Yong-Rui Zou, Anne Davidson

Summary: TNF inhibitors used for treating inflammatory diseases may cause the development of new autoantibodies and secondary autoimmune diseases. TNF deficiency can induce the production of TH17 T cells and enhance the production of germline encoded, T-dependent IgG anti-cardiolipin antibodies. However, it does not induce germinal center formation or precipitate clinical disease. Additional immune stimuli can restore germinal center formation and induce pathogenic autoimmunity in TNF-deficient mice via extrafollicular pathways or atypical germinal center-like pathways.

JCI INSIGHT (2022)

Article Multidisciplinary Sciences

T cell immunity against liver cancer in mice

John C. McVey, Benjamin L. Green, Benjamin Ruf, Justin D. McCallen, Simon Wabitsch, Varun Subramanyam, Laurence P. Diggs, Bernd Heinrich, Tim F. Greten, Chi Ma

Summary: Non-alcoholic fatty liver disease (NAFLD) has a significant impact on liver cancer development and may impair antigen-specific CD8 (+) T cell immunity due to accumulated macrophages in the liver environment.

ISCIENCE (2022)

Article Gastroenterology & Hepatology

Metformin treatment rescues CD8+T-cell response to immune checkpoint inhibitor therapy in mice with NAFLD

Simon Wabitsch, Justin D. McCallen, Olena Kamenyeva, Benjamin Ruf, John C. McVey, Juraj Kabat, Juliane S. Walz, Yaron Rotman, Kylynda C. Bauer, Amanda J. Craig, Marie Pouzolles, Ira Phadke, Vanessa Catania, Benjamin L. Green, Claude Fu, Laurence P. Diggs, Bernd Heinrich, Xin Wei Wang, Chi Ma, Tim F. Greten

Summary: Non-alcoholic steatohepatitis (NASH) negatively affects the efficacy of immune checkpoint inhibitor (ICI) therapy in hepatocellular carcinoma (HCC). This study reveals that NASH alters the metabolism, function, and motility of hepatic CD8+ T cells, leading to reduced responsiveness to anti-PD-1 treatment. The efficacy can be rescued by metformin treatment.

JOURNAL OF HEPATOLOGY (2022)

Letter Oncology

Soluble E-Cadherin as a Potential Biomarker in Hereditary Diffuse Gastric Cancer Syndrome

Martha E. Teke, Lauren A. Gamble, Sarah G. Samaranayake, Benjamin L. Green, Areeba Saif, Jonathan M. Hernandez, Jeremy L. Davis

ANNALS OF SURGICAL ONCOLOGY (2022)

Article Endocrinology & Metabolism

Novel GLCCI1-BRAF fusion drives kinase signaling in a case of pheochromocytomatosis

Benjamin L. Green, Robert R. C. Grant, Christopher T. Richie, Bishwanath Chatterjee, Michelly Sampaio De Melo, Frederic G. Barr, Karel Pacak, Sunita K. Agarwal, Naris Nilubol

Summary: This study reports the discovery and characterization of a novel BRAF-containing fusion transcript in a patient with recurrent PCC, leading to activation of the MAPK signaling pathway and upregulation of EMT markers. The findings suggest potential benefits of clinically available MEK and/or BRAF inhibitors for this patient.

EUROPEAN JOURNAL OF ENDOCRINOLOGY (2022)

Article Genetics & Heredity

Frequent cleft lip and palate in families with pathogenic germline CDH1 variants

Benjamin L. Green, Grace-Ann Fasaye, Sarah G. Samaranayake, Anna Duemler, Lauren A. Gamble, Jeremy L. Davis

Summary: Pathogenic and likely pathogenic variants in the CDH1 gene are associated with increased risk of gastric and breast cancers, as well as hereditary cleft lip and palate (CLP). This study aimed to determine the prevalence of CLP in families with these variants. The results showed a high prevalence of CLP in families carrying CDH1 variants, with no clear genotype-phenotype pattern. Genetic testing for CDH1 should be considered in families with CLP and a history of gastric or lobular breast cancer.

FRONTIERS IN GENETICS (2022)

Article Oncology

Cytoreduction and HIPEC for Gastric Carcinomatosis: Multi-institutional Analysis of Two Phase II Clinical Trials

Benjamin L. Green, Alisa N. Blumenthaler, Lauren A. Gamble, James D. McDonald, Kristen Robinson, Maureen Connolly, Monica Epstein, Jonathan M. Hernandez, Andrew M. Blakely, Brian D. Badgwell, Jeremy L. Davis

Summary: CRS-HIPEC treatment for gastric adenocarcinoma with peritoneal metastasis showed a 3-year survival rate of 22% and common complications. The number of lymph node metastases was inversely correlated with overall survival.

ANNALS OF SURGICAL ONCOLOGY (2023)

Article Gastroenterology & Hepatology

Immunosuppressive CD29+ Treg accumulation in the liver in mice on checkpoint inhibitor therapy

Benjamin L. Green, Yuta Myojin, Chi Ma, Benjamin Ruf, Lichun Ma, Qianfei Zhang, Umberto Rosato, Jonathan Qi, Mahler Revsine, Simon Wabitsch, Kylynda Bauer, Mohamed-Reda Benmebarek, Justin Mccallen, Amran Nur, Xin Wang, Vivek Sehra, Revant Gupta, Manfred Claassen, Xin Wei Wang, Firouzeh Korangy, Tim F. Greten

Summary: CD29(+) Tregs constitute a unique subpopulation of hepatic Tregs that are highly proliferative and play a critical role in mediating resistance to immune checkpoint inhibitor therapy. They respond to alpha PD-1 and double in size, regardless of the presence of an intrahepatic tumor. IL2 is identified as a critical modulator of both CD29(+) and CD29(-) hepatic Tregs, but IL2-independent expansion of the liver Treg population is driven by CD29(+) Tregs.
Article Medicine, Research & Experimental

Combination of AFP vaccine and immune checkpoint inhibitors slows hepatocellular carcinoma progression in preclinical models

Xinjun Lu, Shanshan Deng, Jiejie Xu, Benjamin L. Green, Honghua Zhang, Guofei Cui, Yi Zhou, Yi Zhang, Hongwei Xu, Fapeng Zhang, Rui Mao, Sheng Zhong, Thorsten Cramer, Matthias Evert, Diego F. Calvisi, Yukai He, Chao Liu, Xin Chen

Summary: Combining AFP vaccine with immune checkpoint inhibitors may be effective for treating AFP (+) HCC patients who do not respond to first-line treatment.

JOURNAL OF CLINICAL INVESTIGATION (2023)

Article Oncology

Cytoreduction and HIPEC for Gastric Carcinomatosis: Multi-institutional Analysis of Two Phase II Clinical Trials

Benjamin L. Green, Alisa N. Blumenthaler, Lauren A. Gamble, James D. McDonald, Kristen Robinson, Maureen Connolly, Monica Epstein, Jonathan M. Hernandez, Andrew M. Blakely, Brian D. Badgwell, Jeremy L. Davis

Summary: In patients with gastric adenocarcinoma and isolated peritoneal metastasis treated with CRS-HIPEC, the 3-year overall survival rate from CRS-HIPEC was 22%, and complications were common. The number of pathologic lymph node metastases was inversely correlated with overall survival.

ANNALS OF SURGICAL ONCOLOGY (2023)

Article Gastroenterology & Hepatology

Anti-PD-1 in Combination With Trametinib Suppresses Tumor Growth and Improves Survival of Intrahepatic Cholangiocarcinoma in Mice

Simon Wabitsch, Mayank Tandon, Benjamin Ruf, Qianfei Zhang, Justin D. McCallen, John C. McVey, Chi Ma, Benjamin L. Green, Laurence P. Diggs, Bernd Heinrich, Tim F. Greten

Summary: The study demonstrated that trametinib enhances the immunogenicity of tumor cells by up-regulating MHC-I surface expression and when combined with anti-PD-1, resulted in optimal treatment efficacy for iCCA, particularly in SB1 tumor models. Whole-exome sequencing of SB1 cells suggests that even KRAS wild-type iCCAs respond well to this combination therapy.

CELLULAR AND MOLECULAR GASTROENTEROLOGY AND HEPATOLOGY (2021)

No Data Available